Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: Its possible clinical significance
Response to platinum retreatment in recurrent epithelial ovarian cancer is related to the platinum-free interval (PFI). The recommended and most accepted chemotherapy in the treatment of platinum-sensitive (PFI > 6 months) recurrence is platinum-based combination regimens. Patients with a PFI of...
Main Authors: | Yin-Ting Chuang, Chih-Long Chang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2012-09-01
|
Series: | Taiwanese Journal of Obstetrics & Gynecology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1028455912001179 |
Similar Items
-
Progress of Surgery on Platinum-sensitive Recurrent Ovarian Cancer
by: HE Liya, et al.
Published: (2021-09-01) -
Introduction to managing patients with recurrent ovarian cancer
by: Hani Gabra
Published: (2014-12-01) -
Platinum-sensitive recurrence in ovarian cancer: The role of tumor microenvironment
by: Jeremy eChien, et al.
Published: (2013-09-01) -
The role of topotecan in prolongation of platinum-free interval in patients with recurrent ovarian cancer
by: E U Moskovskaya, et al.
Published: (2014-03-01) -
The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial
by: Hongyuan Gu, et al.
Published: (2020-06-01)